ExpreS2ion Biotechnologies - Presentation of Q2 2024 report (Recording)
Today, ExpreS2ion Biotechnologies’ CEO Bent U. Frandsen and CFO Keith Alexander presented the results and update on business for the second quarter of 2024. Furthermore they gave some insight into the progress and design of studies on their breast cancer candidate, after achieving CTA earlier this month
Watch the recording here:
https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-half-year-2024-report
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 13:50, 15-08-2024.
ExpreS2ion Biotech Holding
ExpreS2ion Biotech Holding är ett forsknings- och utvecklingsbaserat bolag med en patenterad plattform inom bioteknisk proteinproduktion. Bolaget har sin egen utvecklingspipeline av vaccinkandidater inom COVID-19, bröstcancer, influensa och malaria. Dessutom har bolaget intäkter från försäljning av tillverkningstjänster och plattformslicenser. Bolaget startade 2010 och har sin verksamhet i DTU Forskerpark i Hørsholm.
Read more on company page